Recent Updates
Recently added Catalysts

SAD Dose 1- ABS201 Single Dose

Phase 1

Androgenetic Alopecia (AGA) | Small molecule | Dermatology |Absci Corporation|Last Updated: Sep 3, 2026

Target and mechanism

ModalitySmall molecule

Also known as SAD IV Dose 1 - 150mg ABS201 IV Single Dose

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment227

FDA Designations

No designations recorded

Clinical trial landscape

SAD Dose 1- ABS201 Single Dose · 1 trial · 2 indications

Phase 1 1
NCT07317544Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic AlopeciaAndrogenetic Alopecia (AGA)
RECRUITING227 Analytics
PHASE1RECRUITING
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Androgenetic Alopecia (AGA)Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence rate of treatment-emergent adverse events (TEAEs) and serious TEAEs
From enrollment to the end of the Study (SAD approximately 12 months, MAD approximately 18 months)

Safety assessments based on reporting of Treatment Emergent Adverse Events, together with clinically significant changes in vital signs, 12-lead ECG parameters, physical examination findings and clinical safety laboratory tests, and change in neurobehavioral symptoms (PHQ-9 and GAD-7).

Secondary Endpoints

Pharmacokinetics (PK)
From enrollment to the end of the Study (SAD up to 12 months, MAD up to 18 months)
Pharmacodynamics (PD)
From enrollment to the end of the Study (SAD up to 12 months, MAD up to 18 months)
Immunogenicity
From enrollment to the end of the Study (SAD up to 12 months, MAD up to 18 months)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SAD IV Dose 1 - 150mg ABS201 or PlaceboEXPERIMENTALABS-201 IV Single Dose
SAD IV Dose 2 - 450mg ABS201 or PlaceboEXPERIMENTALSingle Intra-venous dose of active study drug or placebo in Healthy Volunteers
SAD IV Dose 3 - 900mg ABS201 or PlaceboEXPERIMENTALSingle Intra-venous dose of active study drug or placebo in Healthy Volunteers
SAD IV Dose 4 - 1800mg ABS201 or PlaceboEXPERIMENTALSingle Intra-venous dose of active study drug or placebo in Healthy Volunteers
MAD SC Dose 1 - 300mg ABS201 or PlaceboEXPERIMENTALMultiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA
MAD SC Dose 2 - 600mg ABS201 or PlaceboEXPERIMENTALMultiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA
MAD SC Dose 2 - 1200mg ABS201 or PlaceboEXPERIMENTALMultiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA

Interventions

NameTypeDescription
SAD IV Dose 1 - 150mg ABS201 IV Single DoseDRUGABS-201 is an IgG1 monoclonal antibody developed to specifically target the prolactin receptor (PRLR)
Placebo IVDRUGMatching placebo
ABS-201 SC Multiple DosesDRUGMultiple doses of ABS-201 for Subcutaneous injection
Placebo SC InjectionDRUGSubcutaneous Placebo injection for MAD arms
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria (Major): * Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG. * Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analy...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMSep 3, 2026NCT07317544lastUpdatePostDate: changed
MEDIUMSep 3, 2026NCT07317544lastUpdatePostDate: changed